Los Angeles Capital Management LLC lessened its holdings in shares of Immunome, Inc. (NASDAQ:IMNM – Free Report) by 31.8% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 59,417 shares of the company’s stock after selling 27,685 shares during the quarter. Los Angeles Capital Management LLC owned approximately 0.05% of Immunome worth $1,276,000 at the end of the most recent reporting period.
Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. TD Asset Management Inc raised its position in Immunome by 8.3% during the fourth quarter. TD Asset Management Inc now owns 759,192 shares of the company’s stock valued at $16,307,000 after acquiring an additional 57,912 shares in the last quarter. Intech Investment Management LLC raised its position in Immunome by 19.0% during the fourth quarter. Intech Investment Management LLC now owns 27,015 shares of the company’s stock valued at $580,000 after acquiring an additional 4,311 shares in the last quarter. Geode Capital Management LLC raised its position in Immunome by 24.6% during the fourth quarter. Geode Capital Management LLC now owns 2,361,381 shares of the company’s stock valued at $50,731,000 after acquiring an additional 466,806 shares in the last quarter. PSP Research LLC acquired a new position in Immunome during the fourth quarter valued at approximately $542,000. Finally, Profund Advisors LLC grew its holdings in Immunome by 121.7% during the fourth quarter. Profund Advisors LLC now owns 42,700 shares of the company’s stock valued at $917,000 after purchasing an additional 23,440 shares during the last quarter. Institutional investors own 44.58% of the company’s stock.
Analysts Set New Price Targets
IMNM has been the topic of several analyst reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Immunome in a report on Tuesday, April 21st. Wall Street Zen downgraded Immunome from a “hold” rating to a “sell” rating in a report on Saturday, May 30th. Craig Hallum increased their price target on Immunome from $33.00 to $36.00 and gave the company a “buy” rating in a report on Wednesday, March 4th. Leerink Partners lowered their price target on Immunome from $37.00 to $33.00 and set an “outperform” rating on the stock in a report on Friday, May 15th. Finally, Truist Financial increased their price target on Immunome from $36.00 to $37.00 and gave the company a “buy” rating in a report on Thursday, May 28th. Twelve analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $33.17.
Immunome Stock Down 1.3%
Shares of IMNM stock opened at $18.16 on Thursday. The business’s 50 day moving average is $21.92 and its two-hundred day moving average is $21.71. The company has a market cap of $2.06 billion, a PE ratio of -7.63 and a beta of 2.04. Immunome, Inc. has a 12 month low of $7.96 and a 12 month high of $27.65.
Immunome (NASDAQ:IMNM – Get Free Report) last announced its quarterly earnings data on Tuesday, May 12th. The company reported ($0.48) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.60) by $0.12. As a group, equities analysts expect that Immunome, Inc. will post -2.06 EPS for the current fiscal year.
Insider Activity at Immunome
In other news, CFO Max Rosett sold 65,000 shares of the firm’s stock in a transaction on Thursday, April 2nd. The shares were sold at an average price of $21.92, for a total value of $1,424,800.00. Following the sale, the chief financial officer owned 54,037 shares in the company, valued at approximately $1,184,491.04. This trade represents a 54.60% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Jack Higgins sold 9,438 shares of the firm’s stock in a transaction on Thursday, April 2nd. The stock was sold at an average price of $21.64, for a total transaction of $204,238.32. Following the completion of the sale, the insider owned 22,000 shares in the company, valued at approximately $476,080. The trade was a 30.02% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 139,438 shares of company stock worth $2,964,664. Insiders own 7.21% of the company’s stock.
Immunome Company Profile
Immunome, Inc is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome’s approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.
The company’s lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens.
Featured Articles
- Five stocks we like better than Immunome
- Everpure: AI Storage Uncertainty Overshadows Breakneck Growth
- This Tech ETF Is Beating QQQ—and Canada May Be Part of the Reason
- Intel Is the Market’s Most Mispriced AI Hedge
- The Biggest Opportunity From SpaceX’s IPO May Surprise You
Receive News & Ratings for Immunome Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunome and related companies with MarketBeat.com's FREE daily email newsletter.
